Literature DB >> 2330815

Parenteral administration of GM1 ganglioside to presenile Alzheimer patients.

L Svennerholm1, C G Gottfries, K Blennow, P Fredman, I Karlsson, J E Månsson, G Toffano, A Wallin.   

Abstract

The pharmacokinetic parameters of GM1 ganglioside were examined in 16 patients (mean age 64 +/- 5 years) with Alzheimer's disease. The ganglioside was given intramuscularly and subcutaneously. The maximum GM1 blood level was reached after 48-72 h, the subcutaneous route leading to the highest blood levels, but the individual variability was relatively large. When 100 mg GM1 ganglioside was given daily for a week, maximum serum values of 15 to 20 mumol/l were found in 3 patients. The elimination half-life from serum was 60-75 h.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2330815     DOI: 10.1111/j.1600-0404.1990.tb00930.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  10 in total

Review 1.  Cognitive enhancement therapy for Alzheimer's disease. The way forward.

Authors:  L Parnetti; U Senin; P Mecocci
Journal:  Drugs       Date:  1997-05       Impact factor: 9.546

2.  Glycosphingolipids.

Authors:  Elena Chiricozzi; Massimo Aureli; Laura Mauri; Erika Di Biase; Giulia Lunghi; Maria Fazzari; Manuela Valsecchi; Emma Veronica Carsana; Nicoletta Loberto; Alessandro Prinetti; Sandro Sonnino
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 3.650

Review 3.  Advances in the pharmacotherapy of Alzheimer's disease.

Authors:  J C Soares; S Gershon
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

Review 4.  Clinical pharmacokinetics of drugs for Alzheimer's disease.

Authors:  L Parnetti
Journal:  Clin Pharmacokinet       Date:  1995-08       Impact factor: 6.447

5.  A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients.

Authors:  Jay S Schneider; Stephen M Gollomp; Stephanie Sendek; Amy Colcher; Franca Cambi; Wei Du
Journal:  J Neurol Sci       Date:  2012-11-28       Impact factor: 3.181

6.  GM1 Oligosaccharide Crosses the Human Blood-Brain Barrier In Vitro by a Paracellular Route.

Authors:  Erika Di Biase; Giulia Lunghi; Margherita Maggioni; Maria Fazzari; Diego Yuri Pomè; Nicoletta Loberto; Maria Grazia Ciampa; Pamela Fato; Laura Mauri; Emmanuel Sevin; Fabien Gosselet; Sandro Sonnino; Elena Chiricozzi
Journal:  Int J Mol Sci       Date:  2020-04-19       Impact factor: 5.923

Review 7.  Gangliosides: Treatment Avenues in Neurodegenerative Disease.

Authors:  Pierre J Magistretti; Fred H Geisler; Jay S Schneider; P Andy Li; Hubert Fiumelli; Simonetta Sipione
Journal:  Front Neurol       Date:  2019-08-06       Impact factor: 4.003

Review 8.  GM1 Ganglioside Is A Key Factor in Maintaining the Mammalian Neuronal Functions Avoiding Neurodegeneration.

Authors:  Elena Chiricozzi; Giulia Lunghi; Erika Di Biase; Maria Fazzari; Sandro Sonnino; Laura Mauri
Journal:  Int J Mol Sci       Date:  2020-01-29       Impact factor: 5.923

9.  Intracerebroventricular Infusion of Gangliosides Augments the Adult Neural Stem Cell Pool in Mouse Brain.

Authors:  Yutaka Itokazu; Dongpei Li; Robert K Yu
Journal:  ASN Neuro       Date:  2019 Jan-Dec       Impact factor: 4.146

Review 10.  Gangliosides and the Treatment of Neurodegenerative Diseases: A Long Italian Tradition.

Authors:  Maria Fazzari; Giulia Lunghi; Elena Chiricozzi; Laura Mauri; Sandro Sonnino
Journal:  Biomedicines       Date:  2022-02-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.